P53-DNA Recognition
From Proteopedia
Line 25: | Line 25: | ||
===Domain Architecture and Tetramerization=== | ===Domain Architecture and Tetramerization=== | ||
- | <Structure load='P53tetra.pdb.zip' size='250' frame='true' align='left' caption='Figure 4: Crystal structure of p53 tetramerization domain, PDB ID 1C26.' scene='' /> | + | <Structure load='P53tetra.pdb.zip' size='250' frame='true' align='left' caption='Figure 4: Crystal structure of p53 tetramerization domain, [http://www.rcsb.org/pdb/explore.do?structureId=1c26 PDB ID 1C26]<ref name='tetra'>Jeffrey PD, Gorina S, Pavletich NP. Crystal structure of the p53 tetramerization domain. Science 1995;267:1498-502.</ref> .' scene='Sandbox_Reserved_170/Tetra/1' /> |
<Structure load='3kz8bio.pdb.zip' size='500' frame='true' align='right' caption='Figure 4: Crystal structure of p53 DBD tetramer-DNA complex, PDB ID 3KZ8.' scene='Sandbox_Reserved_170/Complex/6' /> | <Structure load='3kz8bio.pdb.zip' size='500' frame='true' align='right' caption='Figure 4: Crystal structure of p53 DBD tetramer-DNA complex, PDB ID 3KZ8.' scene='Sandbox_Reserved_170/Complex/6' /> | ||
- | The p53 protein consists of the N-terminal transactivation, the DNA binding or core, the tetramerization, and the C-terminal regulatory domain (Figure 3). This Proteopedia page discusses protein-DNA recognition by p53, thus focuses on the DBD of p53. The only other domain for which structural information is available is the <scene name='Sandbox_Reserved_170/ | + | The p53 protein consists of the N-terminal transactivation, the DNA binding or core, the tetramerization, and the C-terminal regulatory domain (Figure 3). This Proteopedia page discusses protein-DNA recognition by p53, thus focuses on the DBD of p53. The only other domain for which structural information is available is the <scene name='Sandbox_Reserved_170/Tetra/1'>tetramerization domain</scene>, which forms as a dimer of dimers with one alpha helix and one beta strand contributed by each p53 monomer. |
The <scene name='Sandbox_Reserved_170/Complex/6'>DBD in tetrameric form binds to a response element</scene>, which consists of two half sites. These decameric half sites can be separated by a spacer of flexible length but in this case the spacer is of length zero base pairs. The <scene name='Sandbox_Reserved_170/Complex/7'>p53 tetramer binds DNA as a dimer of dimers</scene> with each dimer binding to one half site of the response element. | The <scene name='Sandbox_Reserved_170/Complex/6'>DBD in tetrameric form binds to a response element</scene>, which consists of two half sites. These decameric half sites can be separated by a spacer of flexible length but in this case the spacer is of length zero base pairs. The <scene name='Sandbox_Reserved_170/Complex/7'>p53 tetramer binds DNA as a dimer of dimers</scene> with each dimer binding to one half site of the response element. |
Revision as of 00:48, 4 July 2012
This Sandbox is Reserved from 22 April 2012, through 31 August 2012 for use in the course "Protein DNA" taught by Remo_Rohs at the La Canada High School, USA. This reservation includes Sandbox Reserved 169 through Sandbox Reserved 170. |
To get started:
More help: Help:Editing |
This is a joint project of La Canada High School and University of Southern California students, mentored by Professor Remo Rohs.
Contents |
A Base Pairing Variant Enhances p53 Binding to a Response Element
Introduction and Biological Role of the Tumor Suppressor p53

Also known as the Guardian of the Genome, the tumor suppressor p53 is central in the natural defense against human cancer. The protein is activated by stress factors that can compromise the genomic integrity of the cell, and this activation unleashes the function of p53 as transcription factor. It binds as a tetramer (Figure 1) to a large range of DNA response elements. The p53 consensus site (Figure 2) is formed by two decameric half-sites, each containing a core element (red), that are separated by a variable number of base pairs (blue).
Binding of p53 to different response elements leads to distinct biological responses, such as cell-cycle arrest, senescence, or apoptosis. These different pathways correspond, at least in part, to differences in p53-DNA binding affinity and stability, which are determined by specific protein-DNA interactions.
Mutations of p53 residues are associated with 50% of human cancers. Such mutations are predominantly located in the p53-DNA binding domain (DBD) based on an analysis of human tumors (Figure 3). Particularly, arginine residues in the p53-DNA interface were found in tumors with high frequencies.
Structural Description of p53-DNA Complex
Domain Architecture and Tetramerization
|
Proteopedia Page Contributors and Editors (what is this?)
Remo Rohs, Eric Martz, Alexander Berchansky, Julia Tam, Sharon Kim, Bailey Holmes, Angel Herraez, Joseph M. Steinberger, Eran Hodis, Masha Karelina, Michal Harel, Ana Carolina Dantas Machado, Jaime Prilusky, Skyler Saleebyan, Joel L. Sussman, Keziah Kim